Background: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in
chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) in …

Objectives To conduct the direct comparison of abiraterone acetate and docetaxel for first-
line treatment of metastatic castration-resistant prostate cancer (mCRPC) in real-life settings …

Purpose New therapies with diverse mechanisms of action are available for metastatic
castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness …

Background Abiraterone acetate and enzalutamide are standard treatments for
chemotherapy-naive metastatic castration-resistant prostate cancer (CN-mCRPC). The …

Background This research work was aimed at evaluating the incidence and risk factors of
adverse events (AEs) occurring in patients treated with abiraterone acetate (AA) and …

Background: Real-world data on chemotherapy-naïve patients with metastatic castration-
resistant prostate cancer (mCRPC) treated with abiraterone plus prednisone are limited …

Aim: This review aims to summarize published evidence on the real-world (RW) outcomes of
abiraterone or enzalutamide in first-line metastatic castration-resistant prostate cancer …

Introduction Several small studies have reviewed the efficacy of abiraterone acetate plus
prednisolone (AAP) in clinical practice outside a trial setting. We report the largest cohort …

It is of much interest to understand the efficacy of abiraterone acetate (AA) in routine clinical
practice. We assessed the clinical outcome of AA in patients with metastatic castration …

Background Docetaxel-based chemotherapy has been the cornerstone of the management
of symptomatic metastatic castration-resistant prostate cancer (mCRPC) since 2004. This …